Cimzia Registry
Summary:
| HR#: |
18919 |
| PRINCIPAL INVESTIGATOR: |
Lawrence Comerford, , MD, MS |
| SPONSOR: |
|
| TARGET ENROLLMENT: |
10 |
| DISEASE TYPE: |
Crohns Disease |
| BODY LOCATION(S): |
Large Intestine,Other, |
| PRIMARY OBJECTIVE: |
To collect information on the long-term use and safety of Cimzia® as compared to other Crohn’s disease medications prescribed in routine clinical practice. |
| SECONDARY OBJECTIVE(S): |
|
| INCLUSION CRITERIA: |
|
| EXCLUSION CRITERIA: |
|
| TREATMENT GROUPS: |
• There are no required visits, tests, or treatments in this registry. At the regularly scheduled office visits, patients will be asked to provide information regarding their Crohn’s disease symptoms and other relevant information about their health and medications. |
| LENGTH OF STUDY: |
10 years |
| CONTACTS: |
- , (Primary Study Coordinator)
or
- Kyle Orrell, MSHP (DDC Research Program Manager)
843-876-4303 or orrell@musc.edu
- Lawrence Comerford, , MD, MS (Principal Investigator)
(843) 876-4262 or comerfol@musc.edu
|
|